On Jan. 12, O2Micro International Ltd. (NASDAQ:OIIM) announce its financial results for the fourth quarter and fiscal year 2014, ended December 31, 2014, on Wednesday, February 4, 2015. On Friday shares of O2Micro International Ltd. (NASDAQ:OIIM) closed at $2.49. Company’s sales growth for last 5 years was -11.40% and EPS growth for next 5 years is recorded as 19.00%.
On Jan. 12, Coeur Mining, Inc. (NYSE:CDE) announced it has entered into a definitive agreement with a subsidiary of Goldcorp Inc. (NYSE:GG) to acquire 100% of the Wharf gold mine, a producing gold mine located near Lead, South Dakota (“Wharf”) for cash consideration of $105 million. Coeur Mining, Inc. (NYSE:CDE) in last trading activity moved up 7.41% to close at $5.94. Company weekly performance is 1.71% while its quarterly performance stands at 13.79%. Coeur Mining, Inc. (NYSE:CDE) is -50.75% away from its 52 week high.
ARIAD Pharmaceuticals Inc. (NASDAQ:ARIA) announced the European Commission (EC) has endorsed the final opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on Iclusig (ponatinib) following recommendations made by the Pharmacovigilance Risk Assessment Committee. The company said this concludes the European Article 20 review of Iclusig. On Friday shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) closed at $6.24. Company’s sales growth for last 5 years was 45.10% and EPS growth for next 5 years is recorded as 41.40%.
Zacks downgraded shares of PennyMac Mortgage Investment Trust (NYSE:PMT) from an outperform rating to a neutral rating in a report issued on Monday. They currently have $24.00 target price on the stock. PennyMac Mortgage Investment Trust (NYSE:PMT) has 1.59% insider ownership while its institutional ownership stands at 70.30%. In last trading activity company’s stock closed at $22.44.
Acceleron Pharma (NASDAQ:XLRN) SVP Steven D. Ertel sold 2,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $40.58, for a total transaction of $81,160.00. Following the sale, the senior vice president now directly owns 52,656 shares of the company’s stock, valued at approximately $2,136,780.48. On last trading day Acceleron Pharma, Inc. (NASDAQ:XLRN) moved up 1.88% to close at $41.72. Its volatility for the week is 4.13% while volatility for the month is 4.88%. Acceleron Pharma, Inc. (NASDAQ:XLRN) monthly performance is 10.87%.